Akari Therapeutics (NASDAQ:AKTX) will report on H1 2023.
Akari Therapeutics H1 2023 Net Loss Of $2.99M Versus $10.8M A Year Ago, Cash Balance Of Approximately $7.2M Sufficient To Fund Operations Into Q1 Of 2024
Benzinga · 09/29 20:04
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.